Objectives Limited therapeutic options exist for treating severe infections caused by
multidrug-resistant (MDR) and extensively drug-resistant Gram-negative bacteria (GNB). In …

Emerging resistance to colistin in Acinetobacter baumannii clinical strains is concerning
because of the limited therapeutic choices for these important clinical pathogens. We …

Introduction Acinetobacter baumannii is a gram-negative, opportunistic pathogen
responsible for resistant nosocomial infections especially in the intensive care units (ICUS) …

Background Colistin is being increasingly used for treatment of infections caused by
multidrug-resistant Gram-negative bacteria, including Acinetobacter baumannii. Methods …

Cation-dependent inhibition of antimicrobial activity was reported for polymyxin antibiotics.
Ca 2+ and Mg 2+ concentrations recommended by the Clinical and Laboratory Standards …

Aim: The in vitro activity of colistin in combination with sulbactam, netilmicin, and
vancomycin against colistin-resistant A. baumannii strains was investigated. Furthermore …

The emergence of multidrug-resistant Gram-negative bacteria that cause nosocomial
infections is a growing problem worldwide. Colistin was first introduced in 1952 and was …

The alarming rise in antibiotic resistance has led to an increase in patient mortality and
health care costs. This problem is compounded by the absence of new antibiotics close to …

Emerging resistance to colistin in clinical Acinetobacter baumannii isolates is of growing
concern. Since current treatment options for these strains are extremely limited, we …

Combination therapy may be required for multidrug-resistant (MDR) Acinetobacter
baumannii. This study systematically investigated bacterial killing and emergence of colistin …